Abstracts should be submitted in English.

The abstract title and text may not contain trade names.

The abstract should not contain references to author’s affiliation or institution.

At the end of the abstract there should be a Statement of Conflict of Interest (or absence thereof) of all authors.

All communication with the authors will be done electronically (e-mail), so the e-mail address of the author responsible for the presentation must be communicated (any incorrect spelling will be the responsibility of the authors).

After submitting the abstract, you must receive a confirmation email. If you do not receive this email, you must contacts us by email – eventos@lab52.pt.

The Congress Official Agency will inform the acceptance or refusal of the abstract via email, as well as the technical details for the presentation of the work.

The Scientific Committee reserves the right to select the work and its form of presentation.

Authors of abstracts accepted only for publication are allowed to withdraw within one week of notification.

An international panel of experts will review the abstracts.

Before the abstract submission, the presenter author should do the registration in the congress.

Hematology

Immunology

Accreditation and management

Solid Tumors

Microbiology

Animal Sciences

Biotechnology and new applications

Others

Each abstract should not exceed 4000 characters (including spaces and punctuation), excluding the title, authors and declaration of conflicts of interest.

Title:

Maximum length of the title: 20 words. Please make sure to type the title correctly.

Do NOT type the abstract title in capital letters.

The title should clearly define the topic. Do NOT identify your institution in the title.

Do NOT put a full stop after the title.

Body of the abstract: the text should be written and structured as indicated below.

Include 4 paragraph (Introduction, Methods, Results and Conclusion)

Accepted abstracts will be published exactly as submitted. Their revision will not be possible.

At the end of the abstract there should be a Statement of Conflict of Interest (or absence thereof) of all authors

Abstract submission open January 6^th 2025

Deadline abstract submission March 31^st 2025 (23:59:59 – Lisbon time)

Notifications of acceptance of the abstracts and their type (oral communication, e-poster, publication only) will be made by April 15^th 2025

Oral presentation: The best scoring abstracts submitted in this category will be selected for a presentation in one of the parallel sessions. The presentation consists of max. 10 minutes presentation. The presentations itself, must have the slides in english and the oral presentation can be made in the mother tongue.

The abstracts accepted for oral presentation must be sent by May 8^th 2025

E-Poster exhibition: This option is for authors whose abstract has not been selected for oral presentation.

An international panel of experts will review the abstracts. Reviewers will give rankings from 0 to 2.5 points, taking into consideration the following 4 criteria:

Scientific quality

Originality

Interest in the topic

Applicability

After giving the rankings, reviewers will submit the recommended presentation type (oral or e-poster). Oral communications should be selected from the best evaluated abstracts.

Abstracts may be selected for:

Oral presentation

E-poster exhibition

Publication only

Rejection

Only the submitting author will receive a confirmation of acceptance for oral presentation, poster exhibition, publication only or a notice of rejection, by e-mail until April 15^th, 2025.

Authors of abstracts selected for an oral presentation will be informed about the type and date of the session and presentation guidelines will be provided.

E-Poster exhibition will not have oral presentation.

All accepted abstracts will be published in the abstract book.

Withdrawal policy: If authors wish to withdraw their abstracts from presentation or publication they are requested to send a letter via e-mail to the congress agency (eventos@lab52.pt) until April 22^nd, 2025. Consequently, the abstract will not be presented nor published.